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The Experience of Fatigue and Quality of Life in Patients with Advanced Lung
Cancer
Andrea Shaffer
ABSTRACT
Fatigue is the most prevalent and distressing symptom experienced by
patients with advanced lung cancer and especially among those patients
undergoing therapy. Advanced lung cancer and its associated symptoms can
significantly impact the quality of life (QOL) of those who have the disease. The
primary purpose of this study was to measure fatigue levels, characterize the
fatigue experience, and assess for gender differences in perceptions of fatigue
and QOL in patients with advanced lung cancer receiving chemotherapy. The
secondary purpose of the study was to examine practice patterns in the
ambulatory setting regarding the routine assessment of fatigue.
The study was a secondary analysis of a larger study being conducted in
the ambulatory clinics of a large, National Cancer Institute-designated
comprehensive cancer center. The study sample consisted of fifty advanced
lung cancer patients, 25 men and 25 women. Two self-report questionnaires, the
Short-Form 36® (SF-36) Acute Version 1 and Fatigue Symptom Inventory (FSI),
were completed by the subjects after receiving a single cycle of chemotherapy.

iv

A chart audit of the 50 subjects was performed assessing for provider
documentation of fatigue assessment and method(s) utilized.
Subjects ranged in age from 40 to 80, with a mean age of 62.4 years. Of
the 50, 26 patients had Stage IV non-small cell lung cancer. A majority of the
patients were receiving chemotherapy alone and had not received prior
chemotherapy.
The results of this study revealed no significant gender differences in
fatigue severity, frequency, or interference levels. The study results also failed to
confirm gender differences in QOL measures. The chart audit did reveal that the
providers in this study did not consistently assess and document fatigue levels,
with the nurses documenting less frequently than the physicians.
The results of this study did suggest that fatigue levels and QOL are
problematic for patients treated for lung cancer. In an effort to better assist
patients and tailor plans of care, it is vital that practitioners, especially nurses,
assess for fatigue in advanced lung cancer patients.
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Chapter One
Introduction
Fatigue is a symptom that every person will experience at least once, but
usually multiple times during his or her life. In the healthy person, fatigue begins
when the individual physically exerts, experiences stress, or lack of sleep, and
serves as a protective function by signaling the person to restore energy by
resting. A good night’s sleep or a few hours of relaxation will generally revive a
healthy individual to a normal level of functioning (Yarbro, Frogge, & Goodman,
2005). Fatigue as a result of cancer and its treatments differs from acute fatigue
because patients continue to suffer feelings of weakness and tiredness despite
rest (Byar et al., 2006).
Fatigue is the most prevalent and distressing symptom experienced by
patients with cancer and undergoing therapy. Individuals with cancer were the
first to call fatigue a cancer-related symptom. It is estimated that fatigue is
reported by 60 to 100 percent of individuals with cancer during their course of
disease and associated treatment (Yarbro et al., 2005). This symptom affects 70
to 95 percent of patients receiving chemotherapy, radiation therapy, or
biotherapy and lingers in 17 to 40 percent of disease-free cancer survivors
(Lavdaniti et al., 2006).
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Fatigue is a multidimensional, subjective experience with physiologic,
psychological, functional, and social consequences (Donovan & Ward, 2005).
The etiology of fatigue is multifactorial in that it may be related to the disease
itself, to sleep disturbance, to concurrent systemic issues such as anemia or
pain, or to emotional distress (Madden & Newton, 2006). Fatigue is
characterized by subjective signs such as feelings of tiredness, muscle
weakness, negative mood, loss of alertness, and the perception of interference
with daily living activities (Madden & Newton, 2006; Yarbro et al., 2005). The
objective manifestations of fatigue can include weight loss, decreased energy,
apathy, anemia, weakness, lack of motivation, decreased attention, excessive
sleepiness, or alterations in sleep patterns (Yarbro, et al., 2005). Fatigue varies
in unpleasantness, duration and intensity (Byar et al., 2006).
Lung cancer is the second most common cancer diagnosis and is the
leading cause of cancer mortality worldwide. In the United States, the five-year
survival rate across all stages of lung cancer remains at approximately 14% and
has not changed significantly in several decades. The most common symptoms
reported by newly diagnosed lung cancer patients at any stage and for those
undergoing therapy for advanced disease are fatigue along with pain, anorexia,
insomnia, cough and dyspnea (Tanaka et al., 2002). Given this information, it is
vital to improve the quality of life in this patient population and affect the single
most common symptom experienced.
Quality of life (QOL) is a multidimensional phenomenon that can often be
impacted by the experience of living with lung cancer. Lung cancer can
2

positively or negatively influence the physical, social, psychological, and spiritual
dimensions of daily living. Patients with lung cancer report the greatest amount
of psychological stress in comparison with other cancer patients. Disturbances in
QOL are vital to assess during the entire disease continuum (Sarna et al., 2005).
Lung cancer and its associated symptoms have a significant impact on
quality of life of those who have the disease. However, there has been little
research about how gender affects the symptom experience of people with lung
cancer (Hoffman et al., 2007). According to the Centers for Disease Control and
Prevention (2007), lung cancer is the second most common cancer among white,
black, Asian/Pacific Islander, American Indian/Alaska Native, and Hispanic men.
Lung cancer is the second most common cancer among white and American
Indian/Alaska Native women in the United States, and mortality rates in women
are nearly twice that of breast cancer. Lung cancer death rates for U.S. women
are among the highest in the world. There has been a progressive swing in lung
cancer demographics with a significant increase in women patients in the last two
decades (Loevgren et al., 2007).
Fu and colleagues (2005) sought to further characterize the effect of
gender on the clinical features and survival patterns of patients with lung cancer
by analyzing data collected from the National Surveillance, Epidemiology, and
End Results Database (SEER). They found that women were diagnosed at an
earlier age than men, raising the question of gender-specific differences in
susceptibility to carcinogens. However, women statistically have better
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outcomes than men at all stages of disease possibly because of hormonal
influences.
Despite the fact that the demographics of lung cancer are changing from a
predominantly male disease, most studies of symptoms and/or quality of life
(QOL) are based on Caucasian, middle-income men with advanced lung cancer.
Some studies have suggested that the symptom experiences of men and women
with lung cancer are different and that women report more and a greater intensity
of symptoms than men (Loevgren et al., 2007). Also, role differences often exist
between men and women, which could significantly impact the perception of
intensity of symptoms and greatly affect quality of life.
At the 2007 Oncology Nursing Society 32nd Annual Congress, attendees
for a special symposium entitled “Cancer-Related Fatigue: The 6th Vital Sign”
were surveyed about practice patterns in their particular settings and about their
experience in assessing cancer-related fatigue (CRF). The results revealed that
approximately one-third of patients with cancer may not be routinely assessed for
fatigue and of those who are assessed for CRF, likely only half of the acquired
information is being documented. The nurses cited barriers to routine
assessment of this symptom in their practices as time constraints, lack of an
appropriate assessment tool, and lack of an appropriate documentation tool
(Given, 2008).
Statement of Problem
An increasing amount of research is available documenting the
experience of fatigue and its effect on quality of life in women with breast cancer
4

during treatment and in survival phases. Few studies exist that have examined
potential gender differences in the experience of fatigue and perceived impact on
QOL in patients with advanced lung cancer receiving chemotherapy. As the goal
of palliative chemotherapy is symptom control and a majority of lung cancers are
diagnosed in advanced stages, it is imperative that the extent and significance of
the fatigue experience be further defined. The primary purpose of this study was
to measure fatigue levels, characterize the fatigue experience, and assess for
gender differences in perceptions of fatigue and QOL in patients with advanced
lung cancer receiving chemotherapy. The secondary purpose of this study was
to examine practice patterns in the ambulatory setting regarding the routine
assessment of fatigue. As fatigue is identified as a prevalent and distressing
issue in cancer populations, it is important that clinicians are assessing for
fatigue and determining to what extent it may be affecting overall quality of life.
Research Questions
1. What are the reported fatigue levels in advanced lung cancer patients who
have received a single cycle of chemotherapy?
2. Are there gender differences in the severity, frequency, and total interference
of the fatigue experience?
3. Are there gender differences in quality of life in advanced lung cancer
patients?
4. How often are providers assessing lung cancer patients for fatigue and
documenting information obtained?
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5. Which method(s) are utilized to perform fatigue assessment in lung cancer
patients?
Definition of Terms
For the purposes of this study, fatigue and QOL are defined as:
1. Fatigue is a multidimensional concept that includes physical, psychological,
social and spiritual aspects and is characterized by feelings of weakness and
tiredness not fully relieved by rest (Byar et al., 2006).
2. Quality of life is defined as a multidimensional, intricate concept that blends
the physical, functional, psychological, and social well-being of each individual.
(Losito et al., 2006).
Significance to Nursing
Fatigue is a very important concept for healthcare professionals to
examine and attempt to understand. Fatigue is a problem that can lead to other
physiologic and psychologic symptoms that collectively affect every aspect of a
patient’s life and thereby impact overall QOL. Studies have already indicated
gender differences in survival rate and susceptibility in people with lung cancer.
Few studies have defined gender differences in the symptom experiences of
people with lung cancer (Hoffman et al., 2007). Therefore, it is important to
elucidate this information as a first step in tailoring interventions to the particular
needs of the defined population. The assessment and documentation of fatigue
levels and recommended management techniques by practitioners is vital to
making an impact on this very distressing cancer-related symptom.

6

Chapter Two
Review of Literature
Fatigue is the most frequently reported symptom experienced by patients
with cancer across the disease continuum. Fatigue is distressing, greatly
impacts quality of life, and profoundly effects patients’ abilities to function in
routine roles and activities. The severity of the fatigue experience can delay
treatments, persist for months or years, and may be predictive of shorter survival
in particular cancer populations (Beck, Dudley & Barsevick, 2005). Hoffman et
al. (2007) noted that few studies have targeted gender differences in the
symptom experiences of patients with lung cancer, and the results of the studies
have been mixed.
Quality of Life and Fatigue
In 2001, Okuyama et al. conducted a study to determine the prevalence of
interference of daily activity due to fatigue in advanced lung cancer patients, the
correlated factors, and methods to detect at risk patients. The study accrued 157
subjects with advanced stage or recurrent disease, of which the majority were
male, from ambulatory patients at two large academic centers in Japan.
The researchers utilized several instruments to ascertain the information
they were seeking including the Cancer Fatigue Scale (CFS), the Fatigue
Numerical Scale (FNS), and a self-administered questionnaire asking if fatigue
7

had interfered with any of seven domains of their activities of daily living. The
CFS is a 15-item self-rating scale for assessing fatigue in cancer patients that
consists of three subscales and is modeled to assess the multi-dimensional
nature of fatigue. Items are rated on a Likert-type scale with higher scores
indicating more severe fatigue. The FNS is a simplistic tool utilized for assessing
fatigue intensity and patients rate their fatigue experience on an 11-point scale.
The investigators also assessed a broad range of biopsychological factors,
including cancer information and previous history of anti-cancer therapy,
psychological distress, and demographical and social support status using
medical record data, a self-administered questionnaire, and structured interview
(Okuyama et al., 2001).
The investigators found that 81.5% of patients experienced some degree
of fatigue and that one-third of patients reported that fatigue had interfered with
physical activities such as walking or normal work. One fifth of the patients
reported that fatigue had interfered with emotional activities such as mood or
enjoyment of life and half of the patients were found to have clinical fatigue.
Depression was also found to be a correlated factor for fatigue (Okuyama et al.,
2001). Limitations of this study are the lack of gender representation and
therefore, lack of ability to generalize results to entire population of advanced
lung cancer patients.
Tanaka and colleagues (2002) investigated how often fatigue, dyspnea,
and pain interfered with daily living activities, whether any differences existed in
the characteristics of these symptoms regarding impact on daily life activities,
8

and whether an 11-point numerical scale was appropriate for screening for those
symptoms interfering with at least one daily life activity in ambulatory patients
with advanced lung cancer. The study accrued 171 patients and again a majority
of the patients were male. Subjects were recruited from ambulatory lung cancer
clinics in two large academic centers in Japan.
The researchers utilized a questionnaire to be completed by the subjects
at home and then returned in the mail. If any items were left blank, telephone
inquiry was used to obtain missing data. The severity of dyspnea, pain, and
fatigue were evaluated with an 11-point numerical scale with the higher the rating
correlating with a greater symptom distress. Another questionnaire, which was a
modified version of the Brief Fatigue Inventory (BFI), was used to assess the
impact of the three symptoms on daily living activities in the previous 24 hours.
The responses were either “presence” or “absence” of interference.
Demographic information and medical information were obtained from medical
record review (Tanaka et al., 2002).
The investigators found that fatigue interfered with at least one daily life
activity in 52% of subjects and mood and enjoyment were disturbed in
approximately 20% with fatigue rated as severe as a seven. Dyspnea interfered
with at least one daily life activity in 55% of subjects, but subjects did not
experience as significant a disturbance in mood and enjoyment. Limitations of
the study were that 74% of subjects had an Eastern Cooperative Oncology
Group Performance Status (ECOG PS) of one, which is slightly higher than most
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patients in this population, and the tools utilized were not properly validated and
confirmed (Tanaka et al., 2002).
Brown, McMillan, and Milroy in 2005 sought to explore the relationship
between fatigue, physical function, the systemic inflammatory response, and
psychological distress in patients with advanced lung cancer. The study accrued
a total of 55 patients, 38 lung cancer patients and 15 healthy subjects. Of the 38
lung cancer patients, 23 were men and 15 were women. The lung cancer
patients were those diagnosed with locally advanced or metastatic disease and
recruited from two specialty palliative care centers and an associated hospital in
the United Kingdom. The healthy volunteers were age-matched and gendermatched.
The control group and patient group were assessed for fatigue, weakness,
anthropometry, physical function, and psychological distress and several
questionnaires were utilized to assess fatigue, weakness, and psychological
distress. The authors used the Functional Assessment of Chronic Illness
Therapy-Fatigue scale (FACIT-F) to measure fatigue and this tool is a 13-item
subscale of the FACIT-F questionnaire that has subjects score each item on a
zero to four scale (not at all to very much). A low total score represents a high
level of fatigue. The subscale assesses quality of life in cancer patients
experiencing fatigue and other anemia-related symptoms. Weakness was
measured using a simple 10-cm visual analogue scale which ranged from “I don’t
feel weak at all” to “I couldn’t feel any weaker”. Psychological distress was
measured using the Hospital Anxiety and Depression (HAD) scale and this is a
10

14-item self-report questionnaire intended to measure anxiety and depression.
The subjects were asked to score the answer that came closest to how they had
been feeling in the previous week on a scale of zero to three with a higher score
suggestive of psychological distress (Brown, McMillan & Milroy, 2005).
The results revealed that patients with advanced lung cancer had higher
levels of weakness and fatigue and increased psychological distress as
compared to the control group. The authors subdivided the group of cancer
patients on the basis of fatigue and found that fatigue was clearly associated with
poor physical function and more psychological distress (Brown, McMillan &
Milroy, 2005). The comparison to the healthy population was interesting,
however, likely not necessary as it is intuitive that the cancer population will
report more symptoms and higher severity scores.
Dagnelie and colleagues. (2007) conducted a cross-sectional study to
quantify the impact of fatigue, relative to other QOL domains, on overall QOL in
lung and breast cancer patients preceding curative radiotherapy. Their interest
derived from lack of studies on this issue. The study accrued a total of 64
patients with 100% of the breast cancer patients being women and 45% of the
lung cancer patients being women.
The investigators used the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) which is a
30-item cancer-specific core questionnaire that contains five function subscales,
three symptom subscales, and two single items assessing global health and
“overall” QOL, and a number of single items addressing various symptoms and
11

believed financial impact. Subjects were asked to complete the EORTC QLQC30, as well as a demographic profile, prior to beginning radiotherapy (Dagnelie
et al., 2007).
The investigators found that EORTC QLQ-C30 scores revealed
considerable impairment in global health status and overall QOL, especially in
lung cancer patients. Also, significant impairment was noted for the subscales
physical, role and emotional functioning, and for the symptom subscales fatigue,
dyspnea, pain, insomnia, and appetite loss. Lung cancer patients reported being
significantly more tired than breast cancer patients. There was a distinct
correlation between level of fatigue and perceived overall QOL (Dagnelie et al.,
2007). A limitation of this study is the inability to generalize these results into
advanced stages of lung cancer as the subjects in this trial were receiving
curative radiotherapy.
Bozcuk and colleagues in 2006 were interested in exploring disease and
treatment factors that can affect QOL that have not previously been thoroughly
investigated in patients with metastatic non-small cell lung cancer receiving
chemotherapy. The study acquired 50 patients with 46 men and only 4 women.
Thirty-seven of the patients were receiving first line chemotherapy and thirteen
were receiving second line. All subjects had either unresectable stage three or
stage four disease and were seen in ambulatory medical oncology clinics.
The authors also utilized the EORTC QLQ-C30 questionnaire to assess
the various aspects of QOL. The questionnaire was completed prior to the first
cycle, on day seven, and after the completion of the second cycle. The
12

investigators gathered demographic, disease, and treatment data from medical
record review (Bozcuk et al., 2006).
The study results proved quite interesting. The authors found that
baseline QOL affects the change in QOL on chemotherapy in that those patients
with a starting global QOL score less than or equal to 50 saw an increase in
global QOL and physical functioning and a decrease in fatigue after two cycles of
chemotherapy. Conversely, those patients with a starting global QOL score
greater than 50 saw a decline in global QOL and physical functioning, but an
increase in fatigue. Also, patients receiving second line chemotherapy reported
less fatigue while on chemotherapy than those patients receiving first line
chemotherapy (Bozcuk et al., 2006). A definite limitation of this study was the
few number of women represented in the study sample.
Gender and Fatigue
Sarna and Brecht (1997) performed an exploratory study, combining two
studies of women with advanced lung cancer, with the purpose of investigating
the underlying cluster of distressing symptoms experienced by women with
advanced lung cancer and exploring the differences in symptoms among clinical
and demographic variables. The study looked at a combined total of 60 women
accrued in oncology clinics, private practices, and oncology units. Forty were
from a previous descriptive study looking at women with any stage of disease
and twenty were from a current longitudinal trial looking at women with advanced
stage lung cancer. The authors performed a secondary analysis of the forty
women from the previous study. The women ranged in age from 33 to 80 years,
13

were eight-seven percent Caucasian, the majority were married and had nonsmall cell lung cancer in advanced stages.
The Symptoms Distress Scale (SDS) is a 10-item self-report scale
developed for assessing cancer-related symptoms, but for this study was
modified to include 13 items pertinent to lung cancer patients. Items are reported
on a Likert-type scale with rates from one to five and five represents the most
distress. Clinical variables assessed included physical function, presence and
mode of treatment, presence of distant metastases, smoking status, and
presence of comorbid disease which was obtained from Karnofsky Performance
Status rating and medical record data. Demographic variables included race or
ethnicity, age, marital status, employment status, income, and education which
were collected from a demographic form completed by the patients (Sarna &
Brecht, 1997).
Sarna and Brecht (1997) found that fatigue, negative outlook, frequent
pain, and insomnia were the most prevalent and the most seriously rated
symptoms. There were no differences reported in symptom distress by the
presence of distant metastases, comorbid disease, histologic type of lung cancer,
marital status, education, income, or smoking status. Limitations of this study
were small sample size in that essentially only 20 women were actively evaluated
by the study instrument and lack of comparison of women to men to ascertain
whether there were gender differences in symptom experience.
Sarna et al. in 2005 conducted a prospective, cross-sectional, descriptive
study to describe the quality of life (QOL) in women living with non-small cell lung
14

cancer, describe the characteristics of meaning of illness (MOI), and explore the
demographic, clinical, health status, and MOI correlates of QOL. The study
collected data from 217 women, predominantly Caucasian, recruited from
multiple clinical sites in the western, eastern, and southern regions of the United
States. All study participants had been diagnosed at least six months and less
than five years with non-small cell lung cancer.
The investigators utilized several instruments including the QOL ScalePatient Version (QOL-Patient) and the Short Form-36 Item (SF-36). The QOLPatient is a 41-item questionnaire that was used in this study as a cancer-specific
measure of QOL. Each item uses a Likert-type scale on an 11-point range and
consists of four subscales addressing physical, social, psychological, and
spiritual well-being. Subjects responded to questions based on how their cancer
experience affected their quality of life. The SF-36 was used as a generic
measure of health-related QOL and is a 36-item self-report questionnaire that
evaluates physical functioning, bodily pain, role limitations caused by physical
health, role limitations caused by emotional health, emotional well-being, social
functioning, vitality and fatigue, and general health perceptions. Scores range
from 0 to 100 one each subscale and higher scores indicate better QOL.
Meaning of illness (MOI) was assessed using eight cards with individual
statements describing illness in positive or negative terms. All eight cards were
placed in front of the subject at one time and the subject was asked to choose
the card the most represented her view of her illness. The investigators also
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collected data on health status, depressed mood, demographics, and clinical
variables (Sarna et al., 2005).
The researchers found that women reported serious levels of fatigue,
substantial disruptions in psychological well-being, and a strong relationship
between health status and physical QOL. One limitation of the study was that of
the 217 subjects accrued, 184 were Caucasian, thereby making it difficult to
generalize to all the population of women with lung cancer. The investigators did
only include those subjects with non-small cell lung cancer; however, this is of
little consequence as the majority of patients with lung cancer have this histologic
type (Sarna et al., 2005).
Hoffman et al. (2007) studied the relationships among pain, fatigue,
insomnia, and gender while controlling for age, comorbidities, and stage of
cancer. The study was a secondary analysis of a single-blinded, randomized
clinical trial of people with cancer sponsored by the National Cancer Institute and
the National Institute for Nursing Research and the researchers selected only
data on lung cancer patients obtained from the first interview at the time of entry
into the trial.
Participants were accrued from two community oncology programs and
two comprehensive cancer centers. The analysis was completed on 80 patients
ranging from age 41 to 83 years and mostly married Caucasians. The analysis
was divided nearly even at 55% men and 45% women (Hoffman et al., 2007).
The participants were exposed to a 10-session nursing intervention that
lasted 20 weeks. Symptoms were assessed utilizing the Cancer Symptom
16

Experience Inventory which is a self-report instrument of 15 symptoms related to
cancer or its treatment. For this study, the variable assessing the frequency of
fatigue, pain, and insomnia was dichotomized to measure the duration of the
relationships among fatigue, pain, and insomnia in people with a new diagnosis
of lung cancer with 56 days of receiving chemotherapy. Symptoms were rated
on a scale from 0 to 10 with 10 indicating the greatest severity. Comorbidities
were assessed using a modified version of the Comorbidity Questionnaire which
assessed for the presence or absence of 14 various chronic health conditions
(Hoffman et al., 2007).
The investigators found that there were no gender differences in fatigue
reporting, with 98% of men reporting fatigue and 94% of women reporting
fatigue. Of the three symptoms of interest to the authors, the only symptom
reported with higher levels of severity for women than men was insomnia.
Limitations of this study were that it was a secondary analysis and that it was
difficult to ascertain whether the symptoms addressed were related to disease
and treatment or to comorbidities (Hoffman et al., 2007).
Husain et al. in 2007 explored sex differences in fatigue at the end of life.
The investigators hypothesized that a sex difference in fatigue exists and that
sex-specific correlates lie beneath this difference. The study was a three-month
longitudinal study that accrued subjects from a home palliative care program
serving a major urban center. Patients had to be admitted to the palliative care
program to be eligible to participate and were excluded if under the age of 18 and
if cognitively impaired.
17

The study accrued a total of 102 patients with a fairly equal representation
of each sex - 47 men and 55 women. The participants completed questionnaires
at zero, one, three, five, seven, nine, and eleven weeks and the disposition of
patients were followed for 12 months after completion of the study. The
investigators utilized the Brief Fatigue Inventory (BFI) which is a nine-item, selfreport, symptom severity and functional interference scale. The tool measures
the single domain of fatigue severity and a score of greater than 3 was used as a
discontinuance point to identify moderate to severe fatigue. The investigators
also utilized the McGill Quality of Life (MQOL) Questionnaire which is a
multidimensional tool that measures physical, psychological, support, and
existential domains. Scores are reported from 0 to 10 and higher scores
correlate with better QOL (Husain et al., 2007).
The authors of the study found that the prevalence of moderate to severe
fatigue at week zero and over time was significantly higher in women than in
men. Interestingly, no differences in MQOL scores were found between the
sexes. This study was the first such study documenting that women experience
a higher prevalence of fatigue and a marked fatigue severity, at least in the
setting of advanced illness receiving palliative care at home. A limitation of this
study was that it did not elucidate specific cancer diagnosis and therefore, did not
account for specific cancer treatments (Husain et al., 2007)
Loevgren et al. (2007) initiated a study to examine the prevalence and
severity of symptoms and difficulties with functioning in women and men with
inoperable lung cancer. The study looked at these issues at three points close to
18

diagnosis, the extent to which these issues change over time, and patient
characteristics that influence these issues. Loevgren et al. (2007) analyzed data
generated from 159 patients, 70 women and 89 men, who had completed the
EORTC QLQ-C30+ Lung Cancer13 (LC13) at baseline (T1), 1 month (T2), and 3
months (T3) after T1.
The EORTC QLQ-C30 + LC13 is a self-report health-related QOL
instrument that assesses general aspects of health-related QOL through 30
items consisting of five functional scales, three symptom scales, a global health
status/QOL scale, and several single items such as dyspnea and insomnia. The
LC13 module assesses disease-specific symptoms, treatment-related side
effects, and pain medication. Each item is evaluated on a four-point Likert scale
except for the global health status/QOL items and these have responses that
range from “very poor” to “excellent”. However, the global health/QOL scale was
not used in this study (Loevgren, 2007).
The study revealed that the most prevalent symptoms and difficulties with
functioning were associated with fatigue at all time points for both women and
men. However, significantly more women than men reported “feeling tense”,
“worried”, “depressed” and more limited in work/daily activities at baseline and
also reported that at T1, their physical condition or treatments interfered with their
social activities and at T3, they needed to stay in the bed or in a chair for most of
the day. One limitation of this study was the small sample size, but it is difficult to
accrue a large sample of lung cancer patients to these studies as this group is
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typically severely ill and non-random attrition and non-participation is a significant
barrier to accrual (Loevgren et al., 2007).
Fatigue Assessment
Regarding routine assessment of fatigue by clinicians, several studies
have sought to identify potential barriers from the patient, clinician, and system
perspectives. In 2002, Passik et al. conducted a clinical trial to explore patientrelated barriers to communication about fatigue according to the patient
perspective. The study recruited 200 subjects equally from multiple urban and
rural sites in the Community Cancer Care, Inc. network in Indiana. The
investigators utilized the 28-item self-report Fatigue Management Barriers
Questionnaire (FMBQ) and found that 46.7% of the subjects reported that
interventions for fatigue were not being offered as well as 43.1% stated that they
were unaware of any possible treatments for fatigue. This led the investigators to
conclude that physicians and patients seem to have reservations discussing
fatigue as a symptom of the disease and as a consequence of therapy.
Borneman et al. (2007) reported data on the phase one portion of a three
phase five year prospective National Cancer Institute (NCI) - funded clinical trial
seeking to translate the National Comprehensive Cancer Network (NCCN)
Cancer-Related Fatigue Clinical Practice Guidelines in Oncology into practice
and construct a translational interventional model that can be reproduced across
other settings. Phase one of the study examined fatigue-related patient,
professional, and system barriers that hinder routine use of NCCN guidelines
recommendations.
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The trial recruited 69 patients with a known diagnosis of breast, lung,
colon or prostate cancer from one medical oncology adult ambulatory care clinic
at a NCI-designated comprehensive cancer center in Southern California. A
chart audit was conducted to evaluate practitioner practices. The audit revealed
a lack of adherence to guidelines, documentation of fatigue, and referrals for
supportive care. Of note, the greatest adherence was documented for
assessment of anemia at 28.99%. A significant number of the patients (66%)
reported that they had never discussed their complaints of fatigue with their
physician and the prevailing belief (54%) was if fatigue was important, then the
physician would have initiated conversation on this subject. (Borneman et al.,
2007)
Knowles et al. (2000) conducted a survey study of registered nurses
working with the Department of Clinical Oncology at the Cancer Centre in
Edinburgh, UK. The investigators wished to evaluate nurses’ knowledge of
fatigue, assessment practices, and what interventions they employed to address
patient complaints of fatigue. The study revealed that cancer-related fatigue was
identified as a common symptom experienced by a majority of the patients the
respondents cared for and 75% of the respondents reported that they assessed
for fatigue in their patient population. However, the study did not delineate the
methods and depth of fatigue assessment and whether assessment of fatigue
was routinely performed. Of note, nurses utilizing common grading criteria were
more likely to work with patients enrolled on clinical trials.
Summary
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From the review of literature, many of the studies exploring fatigue,
symptom distress, and impact on quality of life in women with lung cancer
specifically were conducted in the 1990s, and the state and rigor of treatment
modalities, even palliative, has changed since that time. The majority of current
studies examining this population have largely not been conducted in the United
States so results are not necessarily generalizable to our population of women
who may have different roles and concerns. Sufficient studies exist to explore
the issue of fatigue and quality of life in the general lung cancer population,
however, most of the participants in these trials were men, rendering the results
not clearly applicable to women. Loevgren et al. (2007) speculates that a lack of
knowledge about differences in symptom experiences between men and women
may impede appropriate intervention from the health care system. Also noted,
was a lack of trials with any interventions to address fatigue and thereby impact
quality of life in this patient population.
Studies suggest that there are many barriers that hinder systematic
assessment, management, and documentation of cancer-related fatigue. In an
effort to breakdown these barriers, further studies of the patterns of clinician and
nursing assessment of fatigue need to be completed.
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Chapter Three
Methods
The purpose of this study was to measure fatigue levels, characterize the
fatigue experience, and assess for gender differences in perceptions of fatigue
and quality of life (QOL) in patients with advanced lung cancer receiving
chemotherapy. The secondary purpose of this study was to examine practice
patterns in the ambulatory setting regarding the routine assessment of fatigue.
This chapter delineates the sample, measurement tools, and procedures utilized
to facilitate obtaining the information sought by the researcher. The chapter ends
with a description of data analysis.
Setting and Sample
This study was a secondary analysis of a larger study that was already
underway in the ambulatory care clinics of a large, National Cancer Institutedesignated comprehensive cancer center. This larger study had accrued over
300 patients at the time of this study and sought to examine the impact and
relationships of stress management and exercise training on QOL during
chemotherapy treatment. Data on fifty subjects, 25 women and 25 men, all with
advanced lung cancer, was extracted and examined to achieve a representative
sample of each gender to assess for any differences in fatigue severity,
frequency, total interference and QOL. Participants were 18 years of age or
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older; capable of speaking and reading standard English; diagnosed with
advanced lung cancer; had not received intravenous chemotherapy
administration in the last two months; were scheduled to receive cytotoxic
chemotherapy as outpatients at the center over a period of at least 14 weeks;
had an ECOG performance status of zero, one, or two; and were able to provide
informed consent.
Instrumentation
Short-Form 36® (SF-36) Acute Version 1
The SF-36 is a multi-purpose, short-form health survey questionnaire
consisting of 36 items. It is a self-report measure designed to assess perceived
health and functioning and contains eight scales: ten physical functioning items,
two social functioning items, four role limitations due to physical problems items,
three role limitations due to emotional problems items, five mental health items,
four energy and vitality items, two pain items, and five general perceptions of
health items. Each scale uses a variety of rating formats and raw scores are
converted to a standard metric. Subjects provide Likert-type responses to
questions regarding perceived ability to complete activities of daily living. Each
item is scored on a scale from 0 to 100 with 0 representing the worst possible
health state and 100 representing the best possible health state (Jenkinson et al.,
1993). The interrelatedness of the psychosocial and functional dimensions of
QOL is correlated with physical functioning, and psychosocial aspects are
measured in terms of social activities and relationships (Losito et al., 2006)
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Reliability and validity.

The SF-36 has subscale reliability coefficients

ranging from 0.76 to 0.93. Content validity and construct validity have been
supported in multiple QOL studies (Ware et al., 2002; Losito et al, 2006)
Fatigue Symptom Inventory (FSI)
The FSI is a 14-item self-report tool that assesses the severity, frequency,
and daily pattern of fatigue, as well as its perceived interference with
performance.

Four items measure severity on separate 11-point scales that

assess most, least, and average fatigue in the past week as well as current
fatigue.

Frequency is measured utilizing two separate items that assess the

number of days in the past week that fatigue was felt as well as the extent of
each day on average fatigue was felt. Perceived interference is measured on
seven separate 11-point scales that assess the degree to which fatigue in the
past week was judged to interfere with general level of activity, ability to bathe
and dress, normal work activity, ability to concentrate, relations with others,
enjoyment of life, and mood. Interference ratings can be added to obtain a total
perceived interference score.

The final item is a diurnal variation measured

using a single item that provides descriptive information about daily patterns of
fatigue (Jacobsen, 2004).
Reliability and validity. The FSI is an established reliable and valid
measurement tool of fatigue in patients with cancer. The Cronbach’s alpha
coefficient ranges from 0.92 to 0.95, with convergent validity supported by
significant correlations with the Profile of Mood States-Fatigue (POMS-F).
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Construct validity was supported by significant correlations with life satisfaction
and depression (Hann et al., 2000).
Demographic Data Form
Demographic data was gathered from existing self-report and medical
record review information collected during enrollment of the subjects. Data
extracted for this study included age, gender, histology, stage of disease, ECOG
status, whether treatment included radiotherapy and/or biologic therapy, previous
chemotherapy, marital status, ethnicity, race, educational status, employment
status, occupations of both subject and spouse, and net household income.
Chart Audit Form
A chart audit form was developed to track provider assessment and
documentation of fatigue levels for the 50 subjects examined in this study. Also,
method of assessment utilized was assessed. Charts were reviewed for use of
any of the five most common tools of fatigue level assessment: a four-point
verbal rating scale (none, mild, moderate, severe); a five-point verbal rating scale
(none, mild, moderate, severe, very severe); an eleven-point numeric scale (0 is
no fatigue and 10 is worst possible fatigue); a four-point numeric scale (Common
Toxicity Criteria of the National Cancer Institute); and a 10cm visual analogue
scale (no fatigue to worst possible fatigue). If present in the documentation, data
was appropriately recorded.
Institutional Approvals
Approval to conduct the larger study had already been obtained from the
Scientific Review Committee (SRC) of the institution from which the subjects
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were accrued and the University of South Florida Institutional Review Board
(IRB). Both entities are in existence to evaluate the validity of a study and to
protect the welfare of any human subjects who chose to participate in this study.
An amendment to the original study was drafted to include the chart audit that
assessed provider practice patterns of assessment and documentation of fatigue
levels and was approved by the University of South Florida IRB.
Procedures
With assistance from the researchers conducting the larger study, the
existing database was queried for an equal number of female and male subjects
with advanced lung cancer who had received at least one cycle of chemotherapy.
The subjects’ FSI and SF-36 questionnaire scores at 5 to 6 weeks after a single
cycle of chemotherapy, as well as pertinent demographic data, were gathered.
Also, the medical record was reviewed for physician and nurse documentation of
fatigue levels and methods of assessment on the baseline office visit and the first
follow-up visit after a single cycle of chemotherapy.
Data Analysis
Descriptive statistics were used to analyze the demographic data including
frequencies, percentages, means, and standard deviations. Gender differences
in fatigue levels and QOL scores were analyzed for statistical significance
utilizing t-tests. Categorical data regarding the absence or presence of fatigue
assessment by the physician and nurse was analyzed utilizing frequencies and
percentages.
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Chapter Four
Results, Discussion and Conclusions
This chapter presents the findings of the study. Included in this chapter
are the results, discussion of the findings and limitations, conclusions, and
recommendations for future research.
Results
The sample consisted of 50 total subjects, 25 women and 25 men. They
ranged in age from 40 to 80 with a mean age of 62.4 (SD=10.1). Of the sample,
64 percent were married and 30 percent were divorced. The majority of the
participants were white, representing 48 of 50 patients. Nearly half of the
subjects reported some college education or specialized training while a quarter
reported a high school graduate level of education (Table 1).
Table 1
Frequency and Percent of Sample Demographic Characteristics
Variable
Gender
Marital Status

Race

Education

Frequency

Percent

Male
Female

25
25

50.0
50.0

Currently
Divorced
Never
Widowed

32
15
2
1

64.0
30.0
4.0
2.0

White
Black/African American
More Than 1 Race

48
1
1

96.0
2.0
2.0

Partial High School (10th & 11th)
High School Graduate
Partial College or Special Training
College or University Grad
Graduate Degree

2
12
21
8
7

4.0
24.0
42.0
16.0
14.0
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The majority (n=22) of subjects were retired. Household incomes were
fairly evenly distributed across a range from $20,000 up to greater than
$100,000, with nine patients preferring not to respond to this particular
demographic question (Table 2).
Table 2
Frequency and Percent of Employment Status and Household Income
Variable

Frequency

Percent

Employment

Retired
Full-time Job
Part-time Job
On leave w/ pay
On leave w/o pay
Disabled

22
7
6
6
5
4

44.0
14.0
12.0
12.0
10.0
8.0

Household
Income

Less than $10,000
$10,000-$19,999
$20,000-$39,999
$40,000-$59,999
$60,000-$100,000
> $100,000
Prefer Not to Answer

5
4
10
6
9
7
9

10.0
8.0
20.0
12.0
18.0
14.0
18.0

All of the subjects in this sample had lung cancer (n=50). Of the 50, 26
patients had Stage IV non-small cell lung cancer, 14 had stage III non-small cell
lung cancer, five had limited stage small cell lung cancer, and five had extensive
stage small cell lung cancer. Approximately one-third of the patients had an
ECOG performance status of 0 and two-thirds had an ECOG of one. The
majority of patients were receiving chemotherapy alone, with only nine receiving
radiation in addition to chemotherapy and nine receiving biotherapy in addition to
chemotherapy. Forty-five subjects had never had chemotherapy before while
five had prior chemotherapy experience (Table 3).
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Table 3
Frequency and Percent of Disease and Planned Concurrent Therapy
Variable

Frequency

Percent

Type of Ca

Lung

50

100.0

ECOG PS

1
0

32
18

64.0
36.0

Stage

IV NSCLC
III NSCLC
Ltd. SCLC
Ext.SCLC

26
14
5
5

52.0
28.0
10.0
10.0

Receiving Radiation

Yes

9

18.0

Receiving Biotherapy

Yes

9

18.0

Previous Chemotherapy

Yes

5

10.0

Fatigue Symptom Inventory (FSI)
Levels, severity, frequency, and total interference of fatigue were
assessed utilizing the FSI self-report questionnaire. Overall fatigue was reported
with a mean of 5.9 (SD=3.0) for the highest level in the past week and a mean of
2.1 (SD=1.9) for the lowest level in the past week. Subjects reported that fatigue
occurred with a mean of 4.7 days in the past seven days. Fatigue was reported
to have been present at a mean of 4.5 hours (SD=3.1) per day (Table 4).
Men reported the highest level of fatigue with a mean score of 6.4
(SD=3.1) and the lowest level with a mean of 2.4 (SD=2.0) in the week preceding
the completion of the questionnaire. Women reported the highest level of fatigue
with a mean score of 5.4 (SD=3.0) and the lowest level with a mean of 1.9
(SD=1.7). Frequency data revealed that out of one week, men reported fatigue
with mean scores of 4.8 days and women with mean scores of 4.6 days (Table
4).
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The overall, total interference scores revealed a mean of 20.3 (SD=19.9).
The rate that fatigue interfered with levels of activity was reported as a mean of
3.9 (SD=3.7). Fatigue interfered with enjoyment of life with mean scores of 3.3
(SD=3.1) and with enjoyment of life with reported mean scores of 3.3 (SD=3.1).
Among the gender specific interference scores, fatigue interfered the most with
levels of activity with a mean of 4.4 (SD=4.3) in men and a mean of 3.3 (SD=3.0)
in women. Fatigue interfered least with ability to bathe and dress self with men
reporting a mean of 1.5 (SD=3.0) and women reporting a mean of 1.0 (SD=1.3)
(Table 5). There were no significant differences in scores between women and
men.
Table 4
Means and Standard Deviations (SD) with Independent t-test Comparison of Severity and Frequency Items
on the FSI Questionnaire
Fatigue in past week
Highest level

Lowest level

Average level

Level now

How many days

How much of the day on average

mean

SD

Overall
Male
Female

5.9
6.4
5.4

3.0
3.1
3.0

1.212

.231

Overall
Male
Female

2.1
2.4
1.9

1.9
2.0
1.7

.981

.332

Overall
Male
Female

4.0
4.4
3.6

2.5
2.6
2.3

1.192

.239

Overall
Male
Female

3.0
3.6
2.5

2.7
3.1
2.2

1.430

.160

Overall

4.7

2.5

Male
Female

4.8
4.6

2.6
2.5

.279

.782

Overall

4.5

3.1

Male

5.2

3.3

1.544

.130

Female

3.8

2.7
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Table 5
Means and Standard Deviations (SD) with Independent t-test Comparison of Interference Items on the FSI
Questionnaire
Fatigue in past week
Rate interfered with level of activity

Rate interfered with ability to bathe and dress
self
Rate interfered with normal work activity

Rate interfered with ability to concentrate

Rate interfered with relations with other people

Rate interfered with enjoyment of life

Rate interfered with mood

Mean

SD

t

p

Overall
Male
Female
Overall
Male
Female

3.9
4.4
3.3
1.2
1.5
1.0

3.7
4.3
3.0
2.3
3.0
1.3

1.107

.274
.275

.862

.393
.395

Overall
Male
Female

3.6
3.8
3.4

3.5
3.9
3.1

.404

.688
.688

Overall
Male
Female

2.7
3.0
2.4

3.1
3.4
2.8

.675

.503
.503

Overall
Male
Female

2.5
3.0
2.0

3.0
3.4
2.6

1.122

.267
.268

Overall
Male
Female

3.3
3.9
2.8

3.1
3.6
2.6

1.313

.195
.196

Overall
Male
Female

3.0
3.6
2.6

3.2
3.7
2.5

1.075

.288
.288

Short-Form-36 (SF-36)
Quality of life was measured utilizing the SF-36 health survey instrument.
Overall physical functioning revealed a mean score of 54.9 (SD=29.7). The
overall mean score for physical role limitations was 34.5 (SD=42.2) and vitality
35.1 (SD=24.2). Both were below the midpoint indicating lower states of health.
The remaining mean scores were nearing or above the midpoint indicating
average to better states of health (Table 6).
Again, no significant gender differences were noted in quality of life
measures. Lower scores on this instrument represent a worse state of health
and higher scores represent a better state of health. Overall, physical functioning
32

was the most affected of the eight domains measured by the SF-36. Men
reported mean scores of 48.6 (SD= 31.2), while women reported mean scores of
61.2 (SD=27.2). Of the eight scales, bodily pain was reported similarly among
this sample with a reported mean score of 69.5 (SD=31.1) in men and 69.9
(SD=26.0) in women (Table 6). Of note, women reported better states of health
than men, but this did not prove to be statistically significant upon analysis.
Table 6
Means and Standard Deviations (SD) with Independent t-test Comparison of Items on the SF-36
Questionnaire
Variable

Physical Functioning

Role Limitations – Physical

Role Limitations – Emotional

Vitality

Mental Health

Social Functioning

Bodily Pain

General Health

Mean

SD

t

p

Overall
Male
Female

54.9
48.6
61.2

29.7
31.2
27.2

-1.522

.135

Overall
Male
Female

34.5
31.0
38.0

42.2
41.0
44.0

-.582

.563

Overall
Male
Female

68.7
62.7
74.7

42.8
45.5
40.0

-.991

.327

Overall
Male
Female

35.1
30.8
39.4

24.2
23.9
24.2

-1.265

.212

Overall
Male
Female

72.0
68.0
76.0

24.2
29.8
16.5

-1.174

.246

Overall
Male
Female

64.0
59.0
69.0

29.2
31.1
26.8

-1.217

.230

Overall
Male
Female

69.7
69.5
69.9

28.4
31.1
26.0

-.049

.961

Overall
Male
Female

45.9
43.7
48.1

19.3
18.2
20.4

-.815

.419

Chart Audit Form
For each of the 50 subjects, physician and nursing documentation was
reviewed at baseline visit and at first visit after chemotherapy for documentation
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of presence of fatigue and method utilized to assess and define fatigue.
Physician documentation of fatigue was noted to occur at a rate of 33% and
nurses at a rate of 21%. The two tools employed by practitioners to assist in
screening for fatigue were the four-point verbal rating scale and the four-point
numeric scale.
Discussion
Demographic Data
Data on the subjects was extracted from a much larger study currently
being conducted in the ambulatory care clinics of a large, National Cancer
Institute-designated comprehensive cancer center. The sample consisted of an
equal number of middle-class, white women and men. All of the participants had
advanced lung cancer and were receiving chemotherapy. Few of the subjects
were receiving concurrent radiation therapy or biotherapy so the results are not
reflective of more vigorous therapy. Also, few of the patients had received prior
chemotherapy so the results are not generalized to those patients who have
received other lines of therapy.
All of the subjects participating on the study had an ECOG PS of zero or
one. An ECOG PS of zero indicates no symptoms and a one indicates minimal
symptoms. The study prohibited patients with an ECOG performance status of
greater than two from participating. Many patients with advanced stages of lung
cancer and a Performance Status two are eligible for palliative chemotherapy
and likely the results are not representative of fatigue levels and quality of life in
this population. The sample was small, predominantly white and gathered from a
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single geographic area; thus, results may not be generalizable beyond this
sample.
Fatigue Symptom Inventory (FSI)
Although the results of this study did not reveal a statistical significance in
the severity, frequency, interference, or patterns of fatigue scores among the
male and female participants, it did reveal some important findings. For the
highest level of fatigue in the past week, men and women reported moderate
levels of fatigue. Men and women reported fatigue on nearly 5 out of 7 days in
the past week. Fatigue, in both genders, interfered mostly with activity levels.
Male participants scored the 14-item fatigue measures consistently higher
than female participants. The rate that fatigue interfered with enjoyment of life in
the past week item revealed a mean score of 3.9 (SD=3.6) for the male subjects
versus 2.8 (SD=2.6) for the female subjects. The rate that fatigue interfered with
relationships with other people and with mood in the past week showed mean
scores of 3.0 (SD=3.4) and 3.6 (SD=3.7) for the male participants respectively,
while the mean scores for the female participants were 2.0 (SD=2.6) and 2.6
(SD=2.5) respectively.
A limitation of this study was that fatigue was measured after the
completion of a single cycle of chemotherapy. Fatigue tends to be cumulative
over the course of multiple cycles of chemotherapy. The scores derived in this
study are likely not reflective of the severity, frequency, interference and patterns
of fatigue patients experience with receiving more than one cycle of
chemotherapy. Also, a majority of the patients on the study were receiving
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chemotherapy alone and for those receiving concurrent radiation therapy or
biotherapy, fatigue may be amplified.
SF-36
Overall, the subjects reported average to better states of health on the
items of this measurement tool. Physical role limitations and vitality scores were
reported below midpoint and indicated perceived lesser states of health.
The study results did not confirm statistically significant gender differences
in quality of life measures. Again, male participants scored all items of the SF-36
lower than female participants. Physical functioning appeared to affect health
scores in men more so than women. Men and women reported similar states of
health for the physical role limitations and bodily pain items. Both reported states
of health below midpoint for physical role limitations and states of health above
midpoint in relation to effect of bodily pain.
Fatigue assessment
As fatigue is the most prevalent and most distressing symptom reported
by advanced lung cancer patients, the need for consistent assessment is
imperative. There are well-established interventions to address the issue of
fatigue in cancer patients. Interventions to impact or alleviate fatigue cannot be
employed if fatigue is not assessed. Significant fatigue can lead to patients
suffering in silence or ceasing therapy prematurely.
While assessment of fatigue may be routinely performed by practitioners
during office visits, the documentation examined in this study does not reflect this
practice. Physicians did document patients’ reports of fatigue more often than
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nurses; however, rates of documentation were still quite low. Both practitioners
utilized the four- point verbal rating scale more frequently than other methods of
fatigue assessment. Several nurses utilized the four-point numeric rating scale;
however, it should be noted that many of the subjects were on a concurrent
chemotherapy trial and data in this format was required to document toxicities. It
is unknown, since symptoms tend to occur in clusters, if other symptoms such as
pain or nausea and vomiting supersede the assessment and documentation of
fatigue in daily practice. The sample examined was small and all the subjects
were recruited from a single ambulatory clinic.
Implications for Nursing
Fatigue and quality of life (QOL) are critical concepts for nurses to seek to
understand. Although this study did not establish statistically significant gender
differences in fatigue and QOL, it did reveal that fatigue is a problem for
advanced lung cancer patients and that QOL is impacted. In an effort to better
support and treat these patients, nurses should be assessing for the presence of
fatigue and incorporating possible interventions into nursing plans of care. Also,
timely assessment of fatigue and subsequent intervention may assist patients in
complying with treatment plans and lessen the incidence of cessation of therapy
due to intolerable toxicity in the form of fatigue.
Provider assessment of fatigue was inconsistently and poorly documented
in this study. In order to develop interventions to assist advanced lung cancer
patients with fatigue and impact QOL, nurses must assess for the presence of
the symptom first. Barriers to assessment of fatigue must be addressed and
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scales that assist in more consistent assessment and documentation of fatigue
must be developed.
Conclusions
No statistically significant gender differences were noted in the levels,
severity, frequency or interference of fatigue in the sample utilized in this study.
Also, no statistically significant gender differences were noted in quality of life
measures. Although there were some trends toward differences in men and
women with advanced lung cancer, no significant differences were found. A
larger sample may reveal a statistical difference which would confer the need to
be aware of this difference when applying interventions to address fatigue. As
fatigue has been shown to be a prevalent and distressing symptom in advanced
lung cancer patients, it is important that as many facets of this issue are explored
and documented by practitioners. For the established interventions to assist in
addressing fatigue and the many implications its presence has and to generally
better serve these patients, assessment and subsequent documentation of
fatigue levels must occur.
Recommendations for future research
Since the data from this study revealed that there was no difference in
reported fatigue levels and quality of life levels between men and women, future
studies should be conducted with larger sample sizes to determine if there exists
a statistical significance. Future studies should also seek to accrue a more
racially diverse sample. Expanding the exploration of practitioner assessment of
fatigue is imperative and should occur in multiple settings to truly establish
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pattern. Further studies as to the actual and perceived barriers to fatigue
assessment and documentation by practitioners are imperative.
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Appendix A: Chart Audit Form

Patient Screened for
Presence and
Severity of Fatigue?

Subject
Number

Date of
Visit

Physician

Nurse

Method or Tool Utilized to Screen?
4 point
verbal
rating
scale

5 point
verbal
rating
scale
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11 point
numeric
scale

4 point
numeric
scale

10cm
visual
analogue
scale

Appendix B: Medical Chart Review Form
ID

__ __ __

GENDER

0 Male

1 Female

HEIGHT __ __ __ inches
WEIGHT Pre-chemo weight: __ __ __ lbs.
GROUP

1 UCO

2 SM

3 EX

4 SMEX

DXDATE Date of initial diagnosis for cancer (physician approval date): __ __ / __ __ / __ __ __
__ (mm/dd/yy)
RCDATE Date of diagnosis of cancer recurrence requiring current chemo: __ __ / __ __ / __ __
__ __ (mm/dd/yy)
CATYPE Cancer type __ __
1. Adrenal
2. Bladder
3. Bone (e.g.,
osteosarcoma)
4. Breast
5. Brain
6. Carcinoid (GI)
7. Cervical
8. Colon
9. Endometrial
10. Esophageal
11. Gastric (Stomach)
12. Kidney
13. Layrnx
14. Leukemia (ALL,
AML, CLL, CML)
15. Lip & Oral cavity

16. Liver
17. Lung
18. Lymphoma (Hodgkins,
NHL, Mycosis Fungoides)
19. Melanoma
20. Merkle Cell
21. Mesothelioma
22. Multiple Myeloma
23. Nasal & Sinus
24. Pharyngeal
25. Neuroblastoma
26. Ovarian
27. Pancreatic
28. Prostate
29. Rectal/Anal
30. Salivary

31. Sarcoma, not
osteosarcoma
32. Squamous Cell
33. Testicular
34. Thyroid
35. Unknown Primary
36. Uterine
37. Vaginal/Vulvar
88. Other:

CATYPE2 Does patient have a second cancer diagnosis?
STAGE Stage at start of chemo:
(Check one)

___
___
___
___
___
___

1
2
3
4
5
6

If yes, enter code from list: __ __
If no, leave blank.

Stage I
Stage II
Stage III
Stage IV
Limited Stage SCLC
Extensive Stage SCLC
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Appendix B: (Continued)
ECOG0 Pre-Chemo ECOG Performance Status (check one):
___ 0 Fully active, able to carry on all pre-disease performance without restriction
___ 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a
light or sedentary nature, e.g., light housework, office work
___ 2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and
about more than 50% of waking hours
___ 3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
___ 4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
Surgery
SURG1D Most recent surgery date: __ __ / __ __ / __ __ __ __ (mm/dd/yy)
SURG2D Previous surgery date: __ __ / __ __ / __ __ __ __ (mm/dd/yy)
SURG3D Previous surgery date: __ __ / __ __ / __ __ __ __ (mm/dd/yy)

Radiation Therapy
XRTC XRT while on study: No 0

Yes 1

XRTCTX Number of XRT treatments while on study: __ __
XRTCDS Total dose of XRT while on study: __ __ __ __
XRTCSD Date of first Tx on study: __ __ / __ __ / __ __ __ __ (mm/dd/yy)
XRTCED Date of last Tx on study: __ __ / __ __ / __ __ __ __ (mm/dd/yy)
XRTP1 XRT prior to current chemo (most recent previous course):

No 0

XRTP1TX Number of treatments during this course: __ __
XRTP1DS Total dose of XRT during this course: __ __ __ __
XRTP1SD Tx Start Date: __ __ / __ __ / __ __ __ __ (mm/dd/yy)
XRTP1ED Tx End Date: __ __ / __ __ / __ __ __ __ (mm/dd/yy)
XRTP2 XRT prior to current chemo (course before most recent previous course): No 0
Yes 1
XRTP2TX Number of treatments during this course: __ __
XRTP2DS Total dose of XRT during this course: __ __ __ __
XRTP2SD Tx Start Date: __ __ / __ __ / __ __ __ __ (mm/dd/yy)
XRTP2ED Tx End Date: __ __ / __ __ / __ __ __ __ (mm/dd/yy)
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Appendix B: (Continued)
Concurrent Hormone Treatment
HORTX1 Hormone treatment while on study:
HORTXTY1 Type of hormone treatment:

No 0

Yes 1

___ 0 None

___ 1 Tamoxifen (Nolvadex)
___ 2 Megestrol (Megase)
___ 3 Leuprolide (Lupron)
___ 4 Gosarelin (Zoladex)
___ 5 Medroxyprogesterone (Provera)
___ 6 Triptorelin (Trelstar)
___ 7 Anastrozole (Armidex)
___ 8 Femara (Letrozole)
HORSD1 Date of first Tx while on study: __ __ / __ __ / __ __ __ __ (mm/dd/yy)
HORED1 Date of last Tx while on study: __ __ / __ __ / __ __ __ __ (mm/dd/yy)

HORTX2 Hormone treatment while on study:

No 0

Yes 1

No 0

Yes 1

Concurrent Biological Treatment
BIOTX Biological treatment while on study:
BIOTXTY Type of biological treatment:

___ 0 None
___ 1 Herceptin (Trastuzumab)
___ 2 BCG (Bacillus Calmete-Guérin)

BIOSD Date of first Tx while on study: __ __ / __ __ / __ __ __ __ (mm/dd/yy)
BIOED Date of last Tx while on study: __ __ / __ __ / __ __ __ __ (mm/dd/yy)

Previous Chemotherapy
PRVCHM Did patient receive chemo prior to the current chemo? No 0

Yes 1

PRVCHMX How many prior courses of chemo did patient receive? __ __
(a course refers to a uniform prescription of chemotherapeutic drugs administered over a
series of cycles, usually 21 day cycles)
CHM1 Chemo prior to current chemo (most recent previous course):
No 0
Yes 1
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Appendix C: Demographic Form

GBI

/ /
/ /

1. Today's date:

(MM/DD/YYYY)

2. Birth date:

(MM/DD/YYYY)

3a. Ethnic group (check one):
Hispanic/Spanish/Latino
Not Hispanic/Spanish/Latino
3b. Racial Background (check one):
American Indian or Alaskan Native
Asian
Black or African American
More than one race (specify):
Native Hawaiian/Pacific Islander
White
4. Marital status (check one):
Never married
Currently married
Separated
Divorced
Widowed
5a. Current living arrangement (check one box):
Live alone
Live with spouse/partner
Live with spouse/partner and children
Live with children (no spouse/partner)
Live with roommate who is not partner
Live with parents
Other (specify):
5b. Number of children living at home (enter 0 if none):
6. How long in current living arrangement (check one):
Less than 1 month
One to 6 months
Seven months to less than 2 years
Two to 5 years
More than 5 years
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Appendix C: (Continued)

7. Level of school completed (check one):
Less than 7th grade
Junior High School (7th, 8th, & 9th grade)
Partial High School (10th or 11th grade)
High School graduate
Partial college or specialized training
College or university graduate
Graduate professional training (graduate degree)
8. Current employment situation (check the one box that applies the most):
A. WORKING
Full time at job
Part time at job
B. ON LEAVE
On leave with pay
On leave without pay
C. NOT
EMPLOYED
Disabled
Seeking work
Retired
Homemaker
Student
9. Which category best describes your usual occupation? If you are not currently
employed, which category best describes your LAST job? (check one):
Professional (e.g., teachers/professors, nurses, lawyers, physicians, & engineers)
Manager/Administrator (e.g., sales managers)
Clerical (e.g., secretaries, clerks, or mail carriers)
Sales (e.g., sales persons, agents, or brokers)
Service (e.g., police, cooks, waiters, or hairdressers)
Skilled Crafts, Repairer (e.g., carpenters)
Equipment or Vehicle Operator (e.g., truck drivers)
Laborer (e.g., maintenance or factory workers)
Farmer (e.g., owners, managers, operators, or tenants)
Member of the military
Homemaker (with no job outside the home)
Other (please describe)
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10. Which category best describes your spouse's usual occupation? If your spouse is not
currently employed, which category best describes his/her LAST job? (check one):
Do not have a spouse
Professional (e.g., teachers/professors, nurses, lawyers, physicians, & engineers)
Manager/Administrator (e.g., sales managers)
Clerical (e.g., secretaries, clerks, or mail carriers)
Sales (e.g., sales persons, agents, or brokers)
Service (e.g., police, cooks, waiters, or hairdressers)
Skilled Crafts, Repairer (e.g., carpenters)
Equipment or Vehicle Operator (e.g., truck drivers)
Laborer (e.g., maintenance or factory workers)
Farmer (e.g., owners, managers, operators, or tenants)
Member of the military
Homemaker (with no job outside the home)
Other (please describe)
11. What is your approximate annual gross income? (check one)
(Remember all information you provide will remain completely confidential)
Less than $10,000
$10,000 - $19,999
$20,000 - $39,999
$40,000 - $59,999
$60,000 - $100,000
Greater than $100,000
Prefer not to answer
12. Approximate annual gross income for your household: (check one box)
(Remember all information you provide will remain completely confidential)
Less than $10,000
$10,000 - $19,999
$20,000 - $39,999
$40,000 - $59,999
$60,000 - $100,000
Greater than $100,000
Prefer not to answer
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Appendix D: FSI Questionnaire

FSI
For each of the following, check one box next to the number that best
indicates how that item
applies to you.
1. Rate your level of fatigue on the day you felt most fatigued during the past
week:
0
1
2
3
4
5
6
7
8
9
10
Not at all
Fatigued

As fatigued
as I could be

2. Rate your level of fatigue on the day you felt least fatigued during the past
week:
0
1
2
3
4
5
6
7
8
9
10
Not at all
Fatigued

As fatigued
as I could be

3. Rate your level of fatigue on the average during the past week:
0
1
2
3
4
5
6
7
8
9
Not at all
Fatigued

10
As fatigued
as I could be

4. Rate your level of fatigue right now:
0
1
2
3
4
5

6

7

8

9

Not at all
Fatigued

10
As fatigued
as I could be

5. Rate how much, in the past week, fatigue interfered with your general level of
activity:
0
1
2
No
Interference

3

4

5

6

7

8

9

10
Extreme
interference

6. Rate how much, in the past week, fatigue interfered with your ability to bathe
and dress yourself:
0
1
2
No
Interference

3

4

5

6

7

8

9

10
Extreme
interference

7. Rate how much, in the past week, fatigue interfered with your normal work
activity (includes both work outside the home and housework):
0
1
2
No
Interference

3

4

5

6
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7

8

9

10
Extreme
interference

Appendix D: (Continued)

8. Rate how much, in the past week, fatigue interfered with your ability to
concentrate:
0
1
2
No
Interference

3

4

5

6

7

8

9

10
Extreme
interference

9. Rate how much, in the past week, fatigue interfered with your relations with
other people:
0
1
2
No
Interference

3

4

5

6

7

8

9

10
Extreme
interference

10. Rate how much, in the past week, fatigue interfered with your enjoyment of
life:
0
1
2
No
Interference

3

4

5

6

7

8

9

10
Extreme
interference

11. Rate how much, in the past week, fatigue interfered with your mood:
0
1
2
No
Interference

3

4

5

6

7

8

9

10
Extreme
interference

12. Indicate how many days, in the past week, you felt fatigued for any part of
the day:
0
1
Days

2

3

4

5

6

7
Days

13. Rate how much of the day, on average, you felt fatigued in the past week:
0
1
2
3
4
5
6
7
8
9
10
None of
the day

The entire
day

14. Indicate which of the following best describes the daily pattern of your
fatigue in the past week:
0
1
2
3
4
Not at all
fatigued

Worse in
Worse in the Worse in the No consistent daily
the morning afternoon
evening
pattern of fatigue
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Appendix E: SF-36

1. In general, would you say your health is

Excellent

Very good

Good

Fair

Poor

2. Compared to one week ago, how would you rate your health in general now?

Much better now than one week ago.............
Somewhat better now than one week ago....
About the same...............................................
Somewhat worse now than one week ago.....
Much worse now than one week ago..............
3. The following items are about activities you might do during a typical day. Does your
health now limit you in these activities? If so, how much?
Yes, limited Yes, limited No, not
a lot
a little
limited at all
a. Vigorous activities, such as running, lifting
heavy objects, participating in strenuous
sports..................................................................
b. Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling or playing
golf.........................................................................
c. Lifting or carrying groceries.....................................
d. Climbing several flights of stairs..............................
e. Climbing one flight of stairs.....................................
f. Bending, kneeling or stooping..................................
g. Walking more than a mile........................................
h. Walking several blocks............................................
i. Walking one block....................................................
j. Bathing or dressing yourself.....................................
4. During the past week, have you had any of the following problems with your work or
other regular dailyactivities as a result of your physical health?
Yes
a. Cut down the amount of time you spent
on work or other activities.................................................................
b. Accomplished less than you would like............................................
c. Were limited in the kind of work or other activities...........................
d. Had difficulty performing the work or other activities
(for example it took extra effort)........................................................
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5. During the past week, have you had any of the following problems with your work or
other regular daily activities as a result of any emotional problems (such as feeling
depressed or anxious)?
Yes No
a. Cut down the amount of time you spent
on work or other activities.................................................................
b. Accomplished less than you would like............................................
c. Didn't do work or other activities as carefully as usual.....................
6. During the past week, to what extent has your physical health or emotional problems
interfered with your normal social activities with family, friends, neighbors, or groups?

Not at all........................
Slightly...........................
Moderately.....................
Quite a bit......................
Extremely.......................
7. How much bodily pain have you had during the past week?

None.....................
Very mild..............
Mild.....................
Moderate...............
Severe...................
Very severe.............
8. During the past week, how much did pain interfere with your normal work (including
both work outside the home and housework)?

Not at all........................
A little bit........................
Moderately.....................
Quite a bit......................
Extremely.......................
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9. These questions are about how you feel and how things have been with you during
the past week. For each question, please give the one answer that comes closest to the
way you have been feeling.
All of
Most of
the time the time

A good
bit of the
time

Some of
the time

A little of
the time

None
of the
time

How much of the time
during the past week:
a. Did you feel full of pep?.............
b. Have you been a nervous
person?......................................
c. Have you felt so down in the
dumps that nothing could cheer
you up?........................................
d. Have you felt calm and
peaceful?...................................
e. Did you have a lot of energy?....
f. Have you felt downhearted and
blue?..........................................
g. Did you feel worn out?...............
h. Have you been a happy person?
i. Did you feel tired?.......................
10. During the past week, how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting with friends, relatives, etc.)?

All of the time...............
Most of the time...........
Some of the time..........
A little of the time.......
None of the time............
11. Please choose the answer that best describes how TRUE or FALSE each of the
following statements is for you.
Definitely
True

Mostly Not
True Sure

a. I seem to get sick a little easier
than other people..........................
b. I am as healthy as anybody I
know..............................................
c. I expect my health to get worse....
d. My health is excellent...................
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Mostly
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Definitely
False
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12. How much nausea have you had during the past week? (Check one)

None.....................
Very mild..............
Mild.....................
Moderate...............
Severe...................
Very severe..........
13. During the past week, how much did nausea interfere with your normal work
(including both work outside the home and housework)? (Check one)

Not at all.................
A little bit................
Moderately.............
Quite a bit..............
Extremely...............
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